Patient Selection for Telehealth Ketamine

Appropriate patient selection is the foundation of safe telehealth ketamine practice. The at-home model's reduced monitoring capability means that the patient selection process must compensate by more rigorously excluding high-risk individuals. This guide covers the clinical criteria that responsible programs apply.

The Purpose of Patient Selection

Patient selection is not a gatekeeping exercise—it is a clinical risk stratification process. The goal is to identify:

1. Patients likely to benefit from the treatment
2. Patients for whom the at-home model is safe
3. Patients who need a different level of care (in-person, higher monitoring) rather than at-home telehealth
4. Patients for whom ketamine is contraindicated regardless of setting

Getting this right protects patients from harm and directs them to the most appropriate treatment for their needs.

Inclusion Criteria: Who Is a Good Candidate

Diagnostic Indication

The patient has a diagnosis for which ketamine has evidence of benefit:

• Major depressive disorder (moderate to severe, with treatment-resistant features)
• PTSD with inadequate response to standard treatment
• Generalized anxiety disorder with inadequate treatment response
• Chronic pain conditions with central sensitization features (with appropriate protocols)
• Other psychiatric conditions with emerging evidence (evaluated case by case)

Treatment History

The patient has tried first-line treatments without adequate response. "Adequate trial" means at least one (preferably two) medications at therapeutic doses for an adequate duration, plus therapy if available.

Psychiatric Stability

The patient is psychiatrically stable:

• No current acute suicidal crisis with plan or intent
• No active psychosis
• No recent (past 3-6 months) psychiatric hospitalization
• Able to consent to treatment and follow instructions

Medical Eligibility

The patient is medically appropriate:

• Blood pressure within acceptable range (e.g., < 150/90 as a typical threshold)
• No significant hepatic impairment
• No significant cardiovascular disease requiring in-room monitoring
• No active substance use disorder
• Not pregnant or breastfeeding

Safe Home Environment

The patient has:

• A private, safe space for sessions
• Ability to have a sitter present for at least the first sessions
• Reliable internet access for telehealth monitoring
• No circumstances making the home unsafe for treatment (domestic violence, severe instability)

Insight and Engagement Capacity

The patient:

• Understands the nature of the treatment and gives informed consent
• Is capable of following preparation and safety protocols
• Is willing to engage with integration work
• Can reliably report symptoms and adverse events

Exclusion Criteria: Who Should Not Receive At-Home Telehealth Ketamine

Absolute Exclusions

Active psychosis: Ketamine can worsen psychotic symptoms. No ketamine in the presence of active psychosis.

Uncontrolled severe hypertension: Blood pressure that cannot be managed within safe parameters precludes ketamine.

Ketamine misuse history: Patients who have misused ketamine or dissociative drugs are not candidates for home-based ketamine prescribing.

Active severe alcohol use disorder: The combination of ketamine and alcohol is dangerous; patients who are actively drinking heavily are not appropriate for at-home treatment.

Allergy to ketamine: Uncommon but absolute exclusion.

Pregnancy: Ketamine effects on fetal development are not adequately studied; ketamine should not be used during pregnancy.

Strong Relative Exclusions (Usually Exclusions)

Active suicidal ideation with plan/intent: These patients need a higher level of care with direct supervision.

Recent psychiatric hospitalization (< 3-6 months): Level of care mismatch.

Serious cardiac history: Requires in-room monitoring capability.

Bipolar I without adequate mood stabilization: Risk of manic switch without ability to intervene.

Active eating disorder with medical instability: Weight-related medical complications may contraindicate.

Significant hepatic disease: Altered ketamine metabolism.

Relative Exclusions (Requiring Careful Clinical Judgment)

History of dissociative episodes or DID: May respond poorly or unpredictably to ketamine's dissociative effects; requires specialist consultation.

History of mania or hypomania (Bipolar II): Requires adequate mood stabilization and monitoring plan.

Moderate substance use disorder in partial remission: Case-by-case evaluation with enhanced monitoring.

Significant chronic pain on opioids: Pharmacological interactions require careful management.

History of severe adverse reactions to ketamine: Requires careful consideration of dose, setting, and monitoring.

Borderline Cases: Requiring Clinical Judgment

Some patients do not clearly fall into included or excluded categories. These borderline cases require individualized clinical judgment:

Passive suicidal ideation without plan: Some patients with chronic passive SI (thoughts of death without plan or intent) can be safely treated in at-home settings with enhanced monitoring. Others cannot. The specific nature of the ideation, its chronicity, and the stability of the home environment all matter.

Bipolar II with good mood stabilization and psychiatrist oversight: Some patients can be safely treated at-home with enhanced monitoring, coordinated care, and explicit protocols. Others should be in-person.

Trauma survivors with PTSD: Can be treated at-home, but require trauma-informed integration support and careful preparation. The quality of the integration plan matters enormously.

Prior history of psychosis in full sustained remission: Long periods of stability and robust psychiatric monitoring may make at-home treatment reasonable for some of these patients.

What Happens When Clinical Judgment Varies

Different telehealth platforms apply exclusion criteria differently. Some are conservative (erring on the side of exclusion for borderline cases); others are more permissive. Permissive patient selection criteria expand access but may increase adverse event rates.

As a patient, if you are rejected by one platform, consider whether that rejection reflects an appropriate safety assessment of your specific situation rather than an arbitrary policy. If you believe the rejection was wrong, seek in-person evaluation at a ketamine clinic where more intensive monitoring is available and clinical judgment can be applied in person.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• HHS: Telehealth — U.S. Department of Health and Human Services guide to telehealth services, regulations, and patient resources
• SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service